There are currently 584 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729
Recruiting
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2025
Locations: Skin Specialists, P.C, Omaha, Nebraska
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752
Recruiting
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: TG Therapeutics Investigational Trial Site, Omaha, Nebraska
Conditions: Relapsing Multiple Sclerosis, Multiple Sclerosis
Register for Updates
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT03331198
Recruiting
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska +1 locations
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Register for Updates
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845
Recruiting
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/28/2025
Locations: Nebraska Methodist Hospital, Omaha, Nebraska
Conditions: Solid Tumors
Register for Updates
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Advanced Surgery Center, Omaha, Nebraska +7 locations
Conditions: Lumbar Spinal Stenosis
Register for Updates
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420
Recruiting
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: GSK Investigational Site, Omaha, Nebraska
Conditions: Neoplasms, Head and Neck
Register for Updates
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588
Recruiting
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: GSK Investigational Site, Omaha, Nebraska
Conditions: Neoplasms, Head and Neck
Register for Updates
A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737
Recruiting
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/28/2025
Locations: Research Site, Omaha, Nebraska
Conditions: Cutaneous Lupus Erythematosus
Register for Updates
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
NCT05849298
Recruiting
The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium \[177Lu\] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans). Approximately 120 participants will be randomized.
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
05/28/2025
Locations: Urology Cancer Center PC, Omaha, Nebraska
Conditions: Prostatic Neoplasm
Register for Updates
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686
Recruiting
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Nebraska Medicine-Village Pointe, Omaha, Nebraska +1 locations
Conditions: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Register for Updates
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202
Recruiting
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Skin Specialists PC, Omaha, Nebraska
Conditions: Chronic Spontaneous Urticaria
Register for Updates
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006
Recruiting
This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced/metastatic adenocarcinoma of the gastric and/or gastroesophageal junction (G/GEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio. Enrolled subjects shall be treated with the study drug until the loss of clinical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Nebraska Cancer Specialists, Omaha, Nebraska
Conditions: Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Register for Updates